Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Callan Capital LLC

Callan Capital LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 2,506 shares of the medical research company’s stock after acquiring an additional 137 shares during the period. Callan Capital LLC’s holdings in Amgen were worth $722,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Briaud Financial Planning Inc acquired a new position in shares of Amgen during the 3rd quarter valued at about $26,000. BOK Financial Private Wealth Inc. acquired a new position in shares of Amgen in the 4th quarter valued at $29,000. OFI Invest Asset Management acquired a new stake in shares of Amgen during the 3rd quarter worth $26,000. Planned Solutions Inc. acquired a new position in Amgen in the fourth quarter valued at $30,000. Finally, Providence Capital Advisors LLC acquired a new stake in Amgen during the third quarter worth about $30,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

AMGN stock traded up $0.60 during trading on Friday, reaching $269.98. 2,436,947 shares of the company’s stock were exchanged, compared to its average volume of 2,822,655. The firm has a market cap of $144.81 billion, a PE ratio of 21.62, a P/E/G ratio of 2.54 and a beta of 0.58. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The company’s fifty day moving average price is $275.10 and its 200-day moving average price is $281.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. During the same quarter in the prior year, the firm posted $4.09 EPS. Amgen’s revenue was up 19.8% compared to the same quarter last year. On average, research analysts expect that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.33%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 72.06%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on AMGN shares. UBS Group dropped their target price on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Truist Financial restated a “buy” rating and set a $320.00 target price on shares of Amgen in a report on Friday, April 12th. TD Cowen lowered their price target on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $329.00 target price on shares of Amgen in a research report on Wednesday, April 3rd. Ten research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $296.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.